吡咯替尼治疗HER2阳性晚期乳腺癌的有效性和安全性

打开文本图片集

中图分类号：R737.9 文献标识码：A文章编号：1006-1959(2025)23-0157-05

DOI:10.3969/j.issn.1006-1959.2025.23.033

Efficacyand Safety of Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

CHENGDaiming,LI Yan

(DepartmentofBreastandThyroidSurgery,theSecondPeople'sHospitalofYibin,Yibin644Ooo,Sichuan,China)

Abstract:ObjectieTanalyetheeficacyandsafetyofpyrotibinthetreatmentofpatientswithhumanepideralgrowthfactoepto -2 (HER2)positiveadvancedbreastcancerMethodsFromJanuary2019toJuly2O24,58patientswithHERpositiveadvancedbreastcancer admitedtotndeoplessialofnreerospeellallofoeresiecudl metastaicsefraleispOei pyrtinibdfsooeddedect wereountedsultsAtotalf58ligiblepatientsreudeditissudeedianSofRpositiedvacdreastanci treatedwith pyrotinib was10.6 months(95%CI 9.1-12.0).ThemedianPFSwas17.1months(95%CI12.7-21.5),ORRwas 35.71% ,and DCR was 92.86%in14advancedfirst-linepatients treatedwithpyrotinib.ThemedianPFSwas11.Omonths(95%C9.0-13.0),ORRwas 24.14% ,andDCR was 93.10% in 29 advanced second-line patients treated with pyrotinib.The median PFS was8.0 months(95%CI: 5.5-10.5),ORR was 20.00% ,and DCR was 86.67 % in15>advancedsecond-linepatients reatedwithpyrotinib.Duringthetreatment,teincidenceof grade3adversereactionswas as follows:diarrhea was 15.52% (9/58),neutropenia was 10.34% (6/58),hand-foot syndrome was 8.62% (5/58),nausea or vomiting was 3.45% （20 (2/58),alanine aminotransferase or aspartate aminotransferase (ALT/AST) increased to 1.72% (1/58),and no grade≥3 thrombocytopenia occurred. ConclusionPatitosidadeevnreantingotibocde reactionscanbe tolerated,which isagood treatment regimen.

Key words：Breast cancer;Pyrotinib;Human epidermal growth factor receptor

2022年我国女性新发乳腺癌达35.72万，虽较前稍有所下降，但仍是造成我国恶性肿瘤疾病负担的重要构成因素。（剩余11170字）